Chronic infusion of beta-adrenoceptor antagonist and inverse agonists decreases elevated protein kinase A activity in transgenic mice with cardiac-specific overexpression of human beta 2-adrenoceptor

J Cardiovasc Pharmacol. 2002 Sep;40(3):448-55. doi: 10.1097/00005344-200209000-00014.

Abstract

Neutral antagonists and inverse agonists can produce different cellular responses in some systems. The effects of chronic (14-day) infusion of three ligands, ICI-118,551, carvedilol, and alprenolol were examined in cardiac tissue from wild-type and transgenic mice with cardiac-specific overexpression of the human beta2-adrenoceptor. These ligands vary in their negative efficacy at the human beta2-adrenoceptor, with two (ICI-118,551 and carvedilol) behaving as inverse agonists and one (alprenolol) behaving as a neutral antagonist. Cardiac tissue from the transgenic mice exhibited elevated levels of protein kinase A activity and G protein receptor kinase-2. Fourteen-day infusions of the three ligands lowered the elevated levels of protein kinase A activity of the transgenic hearts to control levels. Alprenolol and carvedilol also decreased G protein receptor kinase-2 amounts to control levels. The left atria from transgenic mice exhibited an impaired inotropic response to histamine relative to responses of wild-type mice atria. Infusions of the inverse agonists and a neutral antagonist at the beta2-adrenoceptor significantly restored the impaired histamine response. Restoration of protein kinase A activity and the impaired histamine responses in the atria from transgenic mice can be observed following 14-day infusions of both a neutral antagonist and inverse agonists. The reversal of the effects of the transgene by both inverse agonists and a neutral antagonist suggests that agonist occupancy, and not spontaneous activity, of the beta2-adrenoceptor is producing the elevated protein kinase A activity and the impaired histamine response.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adrenergic beta-Agonists / administration & dosage*
  • Adrenergic beta-Antagonists / administration & dosage*
  • Alprenolol / administration & dosage
  • Animals
  • Carbazoles / administration & dosage
  • Carvedilol
  • Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors*
  • Cyclic AMP-Dependent Protein Kinases / metabolism
  • Dose-Response Relationship, Drug
  • Heart Atria / drug effects
  • Heart Atria / enzymology
  • Heart Ventricles / drug effects
  • Heart Ventricles / enzymology
  • Humans
  • Infusion Pumps, Implantable
  • Mice
  • Mice, Transgenic
  • Myocardium / enzymology*
  • Propanolamines / administration & dosage
  • Receptors, Adrenergic, beta-2 / biosynthesis*
  • Receptors, Adrenergic, beta-2 / genetics

Substances

  • Adrenergic beta-Agonists
  • Adrenergic beta-Antagonists
  • Carbazoles
  • Propanolamines
  • Receptors, Adrenergic, beta-2
  • Carvedilol
  • ICI 118551
  • Alprenolol
  • Cyclic AMP-Dependent Protein Kinases